Kailera Therapeutics
Update in progressKLRA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on obesity and related metabolic diseases. Its portfolio spans clinical and preclinical assets across injectable peptides, oral peptides, and oral small molecules. Programs include KAI-9531, an injectable GLP-1/GIP dual agonist; KAI-7535, an oral GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon tri-agonist. Based in Waltham, MA, founded in 2024, Kailera holds exclusive global rights for four metabolic assets outside Greater China.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.22
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Ronald C. Renaud Jr., M.B.A.
- Founded2024
- Employees145
- Websitewww.kailera.com
Identifiers
- ISINUS4829311020
- FIGIBBG01Q3NQQJ1